Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1552W HIGH $3.15
Volume
141.88 K
Value Traded
93.19 K
Short % Float
3.82%
+7.2%Week
+1,440.56%1 Month
+274.69%3 Month
+466%6 Month
-98.28%5 Year
-98.59%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.77 M
EPS (TTM)
-6.83
P/E Ratio
-
Ent. Value
2.01 M
Total Shares
979.52 K
Float Shares
770.00 K
Insiders
21.07%
Institutions
2.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MTNB Catalyst Timeline
Dated clinical, regulatory and corporate events for Matinas Biopharma Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Matinas Biopharma Holdings, Inc.
658Total events
2Upcoming
107Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲AcquiredMAT2203DiscontinuedCorporate
Matinas sells Matinas BioPharma Nanotechnologies, Inc. including MAT2203 and LNC platform to Azurity Pharmaceuticals
fungal infectionssource ↗
▲Partnership / LicenseMAT2203DiscontinuedCorporate
Definitive agreement to sell MAT2203 and LNC platform to Azurity Pharmaceuticals
fungal infectionssource ↗
▼Equity OfferingCorporate
Series D Convertible Preferred Stock and warrants PIPE for $575,000 gross proceeds
▼Going ConcernCorporate
Received notice of non-compliance with NYSE American continued listing standards
▼Restructuring LayoffsCorporate
Received NYSE American non-compliance notice for continued listing standards
▲Management ChangeCorporate
Appointment of Keith Murphy and Edward Neugeboren to Board of Directors
▼Equity OfferingCorporate
Agreement for acquisition of Preferred Stock and warrants for $3.3 million gross proceeds
◆Management ChangeCorporate
Resignation and retirement of founding Chairman Herbert J. Conrad
◆Pipeline PrioritizationMAT2203DiscontinuedCorporate
Exploring strategic alternatives for MAT2203
invasive fungal infectionssource ↗
▼Quarterly UpdateCorporate
Received NYSE American noncompliance notice for failure to hold annual meeting
▼Partnership / LicenseMAT2203DiscontinuedCorporate
Termination of MAT2203 partnership negotiations
invasive fungal infectionssource ↗
▼Program DiscontinuationMAT2203DiscontinuedCorporate
Ceased all product development activities for MAT2203
invasive fungal infectionssource ↗
▼Management ChangeCorporate
Departure of Chief Medical Officer, Chief Business Officer, and Chief Technology Officer
▲Partnership / LicenseMAT2203DiscontinuedCorporate
Signed non-binding term sheet for global licensing rights to MAT2203
invasive aspergillosis and potentially other invasive fungal infectionssource ↗
▲Enrollment UpdateMAT2203DiscontinuedTrial
31 patients enrolled in MAT2203 Compassionate/Expanded Use Access Program, 6 additional under evaluation
invasive fungal infectionssource ↗
●Preclinical PoCPreclinical
Follow-up in vivo studies of LNC-formulated small oligonucleotides targeting IL-17A and TNFα showed less consistent efficacy
inflammatory conditionssource ↗
◆Trial InitiationMAT2203DiscontinuedTrial
Enrollment expected to commence in ORALTO trial
invasive aspergillosissource ↗
▲Full ResultsMAT2203DiscontinuedClinical Data
Successful treatment of patient with limb-threatening Mucor infection under compassionate use program
polymicrobial necrotizing fasciitis with drug-resistant Lichtheimiasource ↗
●Enrollment UpdateMAT2203DiscontinuedTrial
24 patients currently receiving or completed treatment under compassionate use program
invasive fungal infectionssource ↗
◆Oral PresentationMAT2203DiscontinuedPresentation
Fireside chat featuring MAT2203 with antifungal expert Dr. David S. Perlin
invasive aspergillosissource ↗
◆Poster PresentationPresentation
Poster presentation on oral delivery of anti-inflammatory oligonucleotides with LNC platform at ASGCT 2024
●Enrollment UpdateMAT2203DiscontinuedTrial
22 patients enrolled in Compassionate/Expanded Use Access Program
severe fungal infectionssource ↗
▲Preclinical PoCLNC-miriplatinPreclinical
New formulation of LNC-miriplatin developed; in vitro testing showed strong cellular uptake and tumor cell-killing
hepatocellular carcinomasource ↗
▲PublicationMAT2203DiscontinuedPresentation
Publication of in vivo study results in Journal of Antimicrobial Agents and Chemotherapy
pulmonary mucormycosissource ↗
●Poster PresentationPresentation
Poster presentation at ASGCT 27th Annual Meeting on LNC platform for oral delivery of small oligonucleotides
▼Equity OfferingCorporate
Priced $10 million registered direct offering of common stock and warrants
▼Equity OfferingCorporate
Raised $10 million gross proceeds through registered direct offering
▲FDA Feedback ReceivedMAT2203DiscontinuedFDA Meeting
FDA alignment on Phase 3 ORALTO trial design
invasive aspergillosissource ↗
▲Enrollment UpdateMAT2203DiscontinuedTrial
19 patients enrolled in compassionate use program
invasive fungal infectionssource ↗
▲Preclinical PoCPreclinical
Oral delivery of LNC-formulated small oligonucleotides targeting IL-17A and TNFα shows biological activity
inflammation (colitis, psoriasis)source ↗
▲Preclinical PoCLNC-docetaxelPreclinical
Positive in vivo safety data for oral LNC-docetaxel showing no weight loss vs 20% with IV-docetaxel
oncologysource ↗
▲Full ResultsMAT2203DiscontinuedClinical Data
Three patients with invasive fusarium infection achieve complete clinical response with oral MAT2203
invasive fusarium infectionsource ↗
▲Quarterly UpdateCorporate
Regained compliance with NYSE American continued listing standards
◆Reverse Stock SplitCorporate
NYSE American deficiency letter requires reverse stock split or price improvement by March 21, 2024
Past FDA Catalysts and PDUFA Decisions
How MTNB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-12-31 | MAT2203 (oral LNC formulation of amphotericin B) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$1M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 91%
Micro Cap(rank 599 of 658)
Percentile Rank
Matinas Biopharma Holdings, Inc. faces pipeline headwinds (22/100), with $599M risk-adjusted pipeline value, led by Amphotericin B in Candidiasis, Chronic Mucocutaneous (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphotericin B Small moleculeCompletedNCT02629419 | Candidiasis, Chronic Mucocutaneous | Phase 2 | COMPLETED | 4 | Aug 6, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every MTNB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LNC-docetaxel | multiple metastatic and unresectable tumors | 2024-03-27 | no evidence of weight loss; average peak weight loss of 20% with IV-docetaxel; more than 8x greater than IV-docetaxelRead More | Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weiRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sanitam Partners LLC10% Owner | Buy | 703 1,406 held | $1,000.00 | 04/08/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in MTNB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 0.3 % (-25 %) | 8.89 M | 11.48 M |
MTNB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MTNB ranks across every disease it competes in
Competitive Position is a premium feature
See how MTNB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMTNB News
MTNBMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Matinas BioPharma Holdings, Inc. received a notice of non-compliance from NYSE American due to insufficient stockholders' equity. The company reported $1.8 million in equity, below the required $2 million, and has had losses in five recent fiscal years. Matinas submitted a plan to regain compliance, which has been accepted with a deadline of October 2, 2027.
Read more →MTNB▲ +15.7%on this news
GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma
GH Power Inc. has announced a business combination agreement with Matinas BioPharma Holdings, Inc., marking a significant step towards going public. This partnership is expected to bolster GH Power's market position and facilitate its growth in the clean energy and critical materials sectors.
Read more →MTNB▼ -36.4%on this news· ran to -54% by day 1shared move
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Matinas BioPharma has announced a strategic business combination with GH Power to form a publicly traded clean energy company focused on advanced materials and green hydrogen. Concurrently, Matinas will sell its subsidiary, Matinas BioPharma Nanotechnologies, including its lead product candidate MAT2203, to Azurity Pharmaceuticals for up to $21.5 million. This move aims to enhance growth and capitalize on the increasing demand for clean energy solutions.
Read more →MTNBMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma has received a notice from NYSE American regarding non-compliance with listing standards due to insufficient stockholders' equity. The company submitted a plan to regain compliance, which has been accepted, allowing it to continue trading while under review. However, the company has reported losses for five years, raising concerns about its financial stability.
Read more →MTNBMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren to its Board of Directors, effective March 11, 2025. The new members bring extensive experience in the biotech industry, with Murphy taking on the role of Chair of the Nominating and Governance Committee and Neugeboren becoming Chair of the Compensation Committee. The company expresses gratitude to departing directors Matthew Wikler and Natasha Giordano for their service.
Read more →MTNBMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
Matinas BioPharma has entered into a securities purchase agreement for the sale of 3,300 shares of Series C Convertible Preferred Stock, raising $3.3 million. The company appointed Dr. Robin L. Smith to its Board of Directors, enhancing its leadership. The funds will be used for corporate purposes, particularly to support the development of MAT2203, an antifungal drug candidate.
Read more →MTNB▲ +8.8%on this news
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
Matinas BioPharma has appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025. D'An has a strong background in financial oversight and corporate governance, having served in various capacities at public and private companies. Her expertise is expected to enhance the Board's effectiveness during a pivotal time for the company.
Read more →MTNBMatinas BioPharma Receives NYSE Noncompliance Notice
Matinas BioPharma Holdings, Inc. received a notice from NYSE American for not holding its annual stockholder meeting for the fiscal year ending December 31, 2024. The company plans to hold this meeting by December 31, 2025, to regain compliance. This situation raises concerns about its listing status and future operations.
Read more →MTNB▼ -67.9%on this news
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Matinas BioPharma has terminated its partnership negotiations for MAT2203, an oral antifungal treatment, leading to an 80% workforce reduction and the cessation of product development activities. Key executives, including the Chief Medical Officer and Chief Technology Officer, are among those affected by the layoffs. The company is evaluating the potential sale of MAT2203 but faces uncertainties regarding favorable sale conditions. Future developments may include winding down operations or dissolving the company altogether if conditions do not improve.
Read more →MTNBMatinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Holdings, Inc. has reported its financial results for the second quarter of 2024 alongside a business update. The company announced signing a non-binding term sheet granting global rights for its oral antifungal drug MAT2203, targeting invasive aspergillosis. Positive clinical outcomes have been noted in patients receiving MAT2203 under a Compassionate Use program. However, the company continues to experience net losses, and no revenue was reported for the second quarter.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Matinas BioPharma Holdings, Inc. will report its second quarter 2024 financial results on August 14, 2024. The company will also provide a business update during a conference call at 4:30 p.m. Eastern time. The conference call is accessible by phone and a webcast will be available on the company's website. Matinas focuses on innovative therapies using lipid nanocrystal delivery technology, with its lead therapy MAT2203 demonstrating significant potential in treating invasive fungal infections.
Read more →MTNB▲ +6.7%on this news
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Matinas BioPharma announced a successful case of treating a patient with a serious limb-threatening mucor infection using its oral formulation MAT2203. The 22-year-old patient was discharged after six weeks of treatment, having previously experienced severe adverse effects from intravenous amphotericin. The company highlights positive clinical outcomes and ongoing efforts to advance MAT2203 through further trials, including a Phase 3 study aimed at validating its efficacy against invasive fungal infections. MAT2203 is being developed due to its potential to deliver antifungal therapy with reduced toxicity compared to traditional options.
Read more →MTNBMatinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Matinas BioPharma's oral formulation MAT2203, aimed at treating invasive fungal infections, will be showcased in a fireside chat hosted by A.G.P., featuring Dr. David S. Perlin. The discussion will focus on the current antifungal market, MAT2203's clinical potential, and the design of the pivotal ORALTO trial. Previous studies indicate MAT2203's effectiveness in improving patient outcomes, positioning it as a promising treatment alternative. The event is scheduled for June 18, 2024.
Read more →MTNBMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma reported its financial results for Q1 2024, highlighting a net loss of $5.8 million and a significant decrease in cash reserves. The company raised $10 million through financing, intending to fund development programs into 2025. Notably, Matinas is actively pursuing partnerships to advance its MAT2203 therapy into Phase 3 trials for invasive aspergillosis. Positive in vivo results from studies suggest the potential of its lipid nanocrystal platform technology in broader treatment applications.
Read more →MTNBMatinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
Matinas BioPharma announced that its lipid nanocrystal (LNC) platform will be featured in two presentations at the ASGCT Annual Meeting. The presentations will showcase data from studies on the uptake and targeted delivery of small oligonucleotides, emphasizing LNC's ability to efficiently deliver therapeutic agents. Positive findings from both in vitro and in vivo studies support the platform's potential in treating inflammatory diseases. The company is also focused on optimizing LNC formulations to enhance delivery efficiency and increase therapeutic potency.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
Matinas BioPharma Holdings, Inc. announced that it will report its first quarter 2024 financial results on May 9, 2024, and host a conference call to update investors. The company is known for its lipid nanocrystal platform technology, which aims to improve antifungal treatment through its lead product, MAT2203. MAT2203 has shown efficacy in previous trials, providing a safer oral delivery method for antifungal agents. However, the company faces challenges, including the need for regulatory approvals and potential capital requirements for ongoing research and development.
Read more →MTNB▼ -35%on this news
Matinas BioPharma Prices $10 Million Registered Direct Offering
Matinas BioPharma has announced a registered direct offering, pricing 33,333,334 shares of common stock and associated warrants, aiming to raise approximately $10 million. The company intends to use these proceeds primarily for working capital and corporate purposes. The offering is expected to close on April 5, 2024, subject to customary conditions. Matinas BioPharma is known for its innovative lipid nanocrystal technology, which aims to enhance drug delivery and efficacy.
Read more →MTNB▼ -35%on this news
Matinas BioPharma Announces Registered Direct Offering of $10 Million BEDMINSTER, N.J.
Matinas BioPharma Holdings, Inc. announced a registered direct offering of $10 million through the sale of 33,333,334 shares of common stock and related warrants. The offering aims to support the company’s working capital and general corporate purposes, with closure expected by April 5, 2024. The company's lead candidate, MAT2203, has shown promise in prior clinical trials and will undergo further evaluation in a Phase 3 trial.
Read more →MTNBMatinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Matinas BioPharma reported its 2023 financial results while highlighting key advancements in the development of MAT2203, an oral treatment for invasive aspergillosis. The FDA has aligned with Matinas on the Phase 3 ORALTO trial design, which is crucial for the drug's potential commercialization. Additionally, the company's LNC platform demonstrates promising results in both oncology and inflammation treatments, further diversifying its therapeutic pipeline. Overall, Matinas is actively pursuing partnerships to expedite the advancement of MAT2203.
Read more →About Matinas Biopharma Holdings, Inc.
Headquarters1545 ROUTE 206 SOUTH, BEDMINSTER, NJ, 07921
Founded21-07-2014
BIOPHARMAWATCH ELITE PLUS
Trade the next MTNB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime